ArticleACS medicinal chemistry letters2024
Toward Precision Oncology: The Role of TPD in Targeting CDK2 and Beyond.
Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancements in targeted protein degradation (TPD) technologies are spearheading a new era in precision oncology, offering unprecedented avenues for tackling key oncogenic drivers such as Cyclin-dependent kinase 2 (CDK2). As a pivotal regulator of the cell cycle, CDK2's aberrant activity is closely linked with cancer progression, making it a prime target for therapeutic intervention. This Patent Highlight delves into the innovative TPD strategies aimed at CDK2 degradation, illustrating their potential to disrupt cancer cell proliferation and reshape the therapeutic landscape significantly. By extending the focus to other critical proteins within cancer biology, the discussion emphasizes TPD technologies' versatility and transformative potential in delivering targeted, efficacious cancer therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.